Drugs / Polyethylene glycol interferon alpha-2b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06802718 | Jan 2023 → Dec 2026 expected | acute myeloid leukemia | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyethylene glycol interferon alpha-2b | “Polyethylene glycol interferon alpha-2b injection 135 μg/week was subcutaneously given for 6 months.” NCT06802718 ↗ |
| Route | Subcutaneous | “was subcutaneously given” NCT06802718 ↗ |